A Phase 3 interventional study of TAK-438 and Placebo in Gastric Ulcers and Duodenal Ulcers, sponsored by Takeda. Completed at 102 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-02-05.
Sponsored by Takeda · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing vonoprazan in Stomach Ulcer — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Stomach Ulcer.
Among the 10 studies testing vonoprazan in Stomach Ulcer, this one has the largest enrollment, is one of 4 that started in 2011, is one of 8 in phase 3, and was the 1st registered.
116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.
Browse Stomach Ulcer studies →1 of the 10 studies testing vonoprazan in Stomach Ulcer is open now, in 1 country. Recruiting first, the newest first:
Shicai Ye · Sites in China
Ages 18–70
By country, each count listing its studies:
vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →
Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 642 is above the median of 298 across 88 interventional studies indexed under Stomach Ulcer.
Median enrollment 320 across the 10 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 3 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
14 studies in Stomach Ulcer by Takeda: none open now, none under way, none of them phase 3. Of 14 finished, 6 (43%) have results posted.
Among the 14 studies in Stomach Ulcer by Takeda, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2011, is one of 11 in phase 3, and was the 5th registered.
Takeda’s Stomach Ulcer studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing vonoprazan in Stomach Ulcer, from their registry updates:
Among Takeda’s 14 in Stomach Ulcer:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD), compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of non-steroidal anti-Inflammatory drug (NSAID).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: TAK-438 · Drug: Placebo
Drug: TAK-438 · Drug: Placebo
Drug: Lansoprazole · Drug: Placebo
TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
Also known as: AG-1749
TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
Recurrence rate of gastric or duodenal ulcer within 24 weeks
Mucosal defects with a white coating of 3 mm or larger will be determined as ulcers. Recurrence rate of gastric or duodenal ulcer within 24 weeks will be calculated for each treatment group.
Time frame: 24 weeks
Recurrence rate of gastric or duodenal ulcer within 12 weeks
Time frame: 12 weeks
Gastric mucosal injury
Time frame: 24 Weeks
Duodenal mucosal injury
Time frame: 24 weeks
Occurrence rate of hemorrhagic lesion in stomach or duodenum
Time frame: 24 weeks
Time to recurrence of gastric or duodenal ulcer
Time frame: 24 weeks
Showing the first 100 of 102 sites. Choose a country and city above to see the rest.
The record gives a start of Oct 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan